VITURA HEALTH LIMITED (VIT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

VIT - VITURA HEALTH LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0.06
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.099

22 Jul
2024

0.008

OPEN

$0.10

8.79%

HIGH

$0.10

25,092

LOW

$0.10

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

Last ex-div: 04/09 - ex-div 1c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx2.5
DPS All xxxxxxxxxxxxxxx1.0
Sales/Revenue xxxxxxxxxxxxxxx117.3 M
Book Value Per Share xxxxxxxxxxxxxxx6.3
Net Operating Cash Flow xxxxxxxxxxxxxxx9.7 M
Net Profit Margin xxxxxxxxxxxxxxx11.77 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx45.22 %
Return on Invested Capital xxxxxxxxxxxxxxx41.41 %
Return on Assets xxxxxxxxxxxxxxx30.77 %
Return on Equity xxxxxxxxxxxxxxx45.22 %
Return on Total Capital xxxxxxxxxxxxxxx59.02 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx3.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx19 M
Price To Book Value xxxxxxxxxxxxxxx8.19

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.9 M
Capex % of Sales xxxxxxxxxxxxxxx0.79 %
Cost of Goods Sold xxxxxxxxxxxxxxx91 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx6 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Petra Capital

05/06/2024

3

Downgrade to Hold from Buy

$0.09

-9.09%

Petra Capital has downgraded Vitura Health to Hold from Buy with a reduced target price of 9c from 12c.

The company's latest trading update indicated EBITDA margins year-to-date were around 5%, implying a significant downgrade for 2H24 margins, previously 8.7% in 1H24, according to the broker.

Petra Capital points to increased competition in the core cannabis distribution business for the substantial decline from the FY23 EBITDA margin of 17.7%.

The broker makes material changes to its financial estimates with net profit forecast to decline to $3m in FY24 from $6.3m. The broker is looking for management to stabilise unit volumes and EBITDA margins to regain confidence in the strategy update.

FORECAST
Petra Capital forecasts a full year FY24 dividend of 1.00 cents and EPS of 0.50 cents.
Petra Capital forecasts a full year FY25 dividend of 1.00 cents and EPS of 1.00 cents.
Access Stockbroker Research History >

VIT STOCK CHART

FNArena News on VIT

1
In Case You Missed It – BC Extra Upgrades & Downgrades – 07-06-24

Jun 07 2024 - Weekly Reports
2
Australian Broker Call *Extra* Edition – Jun 06, 2024

Jun 06 2024 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – May 29, 2024

May 29 2024 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – May 15, 2024

May 15 2024 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Mar 07, 2024

Mar 07 2024 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL Shares Breaking Free

10:30 AM - Technicals
2
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
3
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
4
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
5
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
6
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
7
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps
8
Is The Long Wait For CSL About To End?

May 30 2024 - Technicals
9
Dr Boreham’s Crucible: Invion

May 13 2024 - Small Caps
10
Dr Boreham’s Crucible: Race Oncology

Apr 09 2024 - Small Caps